Compositions for regenerating defective or absent myocardium
First Claim
1. An injectable graft composition for myocardial tissue regeneration, said composition comprisingan acellular extracellular matrix (ECM) from a mammalian tissue source comprising small intestine submucosa, said ECM comprising transforming growth factor beta (TGF-β
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising a supplemental bioactive component comprising a glycosaminoglycan (GAG) protein, said GAG protein comprising at least 0.1% by weight of said composition, said GAG protein being linked to said ECM, wherein said GAG protein stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.
3 Assignments
0 Petitions
Accused Products
Abstract
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods for regenerating defective or absent myocardium apply a composition to a site of myocardium in need of regeneration using a delivery mode appropriate for the particular formulation.
40 Citations
1 Claim
-
1. An injectable graft composition for myocardial tissue regeneration, said composition comprising
an acellular extracellular matrix (ECM) from a mammalian tissue source comprising small intestine submucosa, said ECM comprising transforming growth factor beta (TGF-β - ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising a supplemental bioactive component comprising a glycosaminoglycan (GAG) protein, said GAG protein comprising at least 0.1% by weight of said composition, said GAG protein being linked to said ECM, wherein said GAG protein stimulates angiogenic effects of FGF-2 and interacts with TGF-β
to control matrix formation and remodeling, wherein, when said composition is administered to damaged or diseased cardiovascular tissue, said composition induces stem cell proliferation and differentiation of stem cells into cardiomyocytes.
- ) and fibroblast growth factor-2 (FGF-2), said ECM further comprising a supplemental bioactive component comprising a glycosaminoglycan (GAG) protein, said GAG protein comprising at least 0.1% by weight of said composition, said GAG protein being linked to said ECM, wherein said GAG protein stimulates angiogenic effects of FGF-2 and interacts with TGF-β
Specification